Novo Nordisk | NVO - Ordinary Share Capital


Novo Nordisk reported DKK4.43B in Ordinary Share Capital for its fiscal quarter ending in June of 2026.





Ordinary Share Capital Change Date
ANI Pharmaceuticals USD 22.49M 760K Dec/2025
Aurora Cannabis CAD 58.95M 2.24M Mar/2026
Bausch Health Companies USD 373.9M 436K Jun/2026
Bristol-Myers Squibb USD 2.04B 1.74B Sep/2025
Canopy Growth CAD 422.07M 53.78M Mar/2026
Corcept Therapeutics USD 107.33M 1.36M Mar/2026
Drreddys Laboratories INR 832.69M 123K Mar/2026
Eli Lilly USD 943.5M 3.33M Mar/2026
GlaxoSmithKline GBP 4.08B 20.6M Jun/2026
Merck USD 2.47B 4.93M Mar/2026
Nektar Therapeutics USD 29.47M 9.09M Mar/2026
Novartis USD 1.9B 7.38M Jun/2026
Novo Nordisk DKK 4.43B 13.25M Jun/2026
Novo Nordisk DKK 4.43B 13.25M Jun/2026
Pacira USD 39.82M 512K Jun/2026
Perrigo USD 138.1M 500K Mar/2026
Phibro Animal Health USD 40.48M 0 Dec/2025
Prestige Brands USD 47.32M 765K Dec/2025
Sanofi EUR 1.21B 8.25M Mar/2026
Supernus Pharmaceuticals USD 58.16M 124K Jun/2026
Zoetis USD 420.35M 4.58M Mar/2026